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Abstract
Background: The literature measuring effects of antidepressant and electroconvulsive therapy
(ECT) for major depression on heart rate variability (HRV) in medically well individuals was
reviewed.
Methods: Fourteen studies evaluating HRV were included. Twenty three pre-post or within group
comparisons were available. Treatment impact on measures of HRV was pooled over studies. We
examined different classes of antidepressants, and for short and long electrocardiogram (ECG)
recordings separately.
Results: Tricyclic antidepressants (TCAs) were associated with declines in most measures of HRV
and significant increase in heart rate (HR) in studies with short recording intervals. No significant
changes were found for longer recording times.
Treatment effects with selective serotonin reuptake inhibitors (SSRIs) were more variable. Short-
recording studies revealed a significant decrease in HR and an increase in one HRV measure. In two
24-hour recording studies no significant changes were observed. No relationship between ECT and
HRV has been established in the literature. The effects of other drugs are reported.
Limitations: Few studies measure the effects of treatment of depression on HRV. Existing studies
have generally used very small samples, employing a variety of measurements and methodologies.
Conclusion: We confirm that TCAs are associated with a large decrease in HRV and increase HR.
However, data for SSRIs is not clear. Although the effect of SSRIs on HRV is weaker than for TCAs,
evidence shows that SSRIs are associated with a small decrease in HR, and an increase in one
measure of HRV. The use of TCAs in depression leads to changes in HRV that are associated with
increased risk of mortality.
Background
Heart rate variability (HRV) refers to the beat-to-beat
alterations in heart rate. Its measurement is used to assess
cardiac autonomic function and it is related to outcomes
following cardiac events [1-5]. There is some evidence that
major depressive disorder (MDD) is associated with
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decreased heart rate variability [6-9], and that medications
used in the treatment of MDD also affect HRV. HRV in
depression and in its treatment is an important issue since
both depression and decreased HRV have been shown to
be predictors of mortality in cardiac patients. Moreover
studies have shown that depression is associated with a
higher rate of development of coronary heart disease and
of death after an index myocardial infarction (MI) [10],
and that a low HRV after MI is associated with considera-
ble risk of mortality [2,11-14] As a result there has been
substantial interest in the relationship of HRV with
depression and with antidepressant medications.
The purpose of the current paper is to provide an overview
of the literature examining the effects of pharmacologic
and physical treatments for depression on HRV in medi-
cally otherwise well patients with MDD. The present
paper describes the methodologies and HRV measures
used in the study of the effects of treatment of depression
on HRV, and reviews the effects of two major classes of
antidepressants on HRV: tricyclic antidepressants (TCAs)
and selective serotonin reuptake inhibitors (SSRIs). In
addition, we review the small group of studies examining
the effects of other antidepressants on HRV, as well as the
effects of electroconvulsive therapy (ECT).
Defining and Measuring Heart Rate Variability
Before reviewing the relationship between HRV and treat-
ments for depression, it is important to first describe
methods for measuring HRV. In studies examining the
effects of treatments for depression on HRV a variety of
measures of HRV have been employed across different
studies, and as a result, there is a lack of consistency in
approach to HRV measurement. Four common
approaches to measurement of HRV (beat-to-beat altera-
tions in heart rate) are: time domain, spectral or frequency
domain, nonlinear, and geometric methods [15,16].
Because time- domain and spectral or frequency domain
methods are the two methods generally used for assessing
the effects of psychiatric treatments for depression on
HRV, we briefly describe these below.
HRV Measures: Time Domain Methods
Time domain methods reflect various statistical
approaches of measuring and representing the differences
in the intervals between adjacent normal R waves, referred
to as normal to normal (NN) intervals, over a specified
period of time [15]. The Task Force of the European Soci-
ety of Cardiology (1996) describes seven time domain
methods. Four of these have been reported in the litera-
ture on HRV and antidepressants. These include SDNN,
(the standard deviation of all NN intervals); SDANN, (the
standard deviation of means of all NN intervals measured
from successive five-minute recording segments over a 24-
hour assessment time) RMSSD, (the square root of the
mean of the sum of squares of differences between all
adjacent NN intervals), and pNN50, (the percentage of
NN interval differences >50 ms from the preceding inter-
val).
Of the four time domain methods, SDNN is the simplest
to compute and the most commonly used measure of
HRV.
The different time domain measures are thought to be
influenced by different factors. Both SDNN and SDANN
are thought to reflect changes of HRV mediated by both
the influence of parasympathetic efferent and sympathetic
efferent nerve factors. RMSSD and pNN50 are thought to
reflect the changes of HRV mainly mediated by parasym-
pathetic efferent nerves [15]. Bigger et al have reported
associations of decreases in time domain measures with
increased cardiac mortality [17,18]. After adjusting for
other risk factors, SDANN emerged as the most powerful
predictor of cardiac mortality, followed by pNN50.
RMSSD and SDNN were less powerful but were still signif-
icant predictors of mortality [18]. Because of the moderate
correlation between heart rate and HRV the coefficient of
variation (CV) calculation is sometimes also reported in
which SDNN in each five minute interval is divided by the
mean NN interval (SDNN/NN) which attempts to control
for differences in heart rate [19].
HRV Measures: Frequency-domain Methods
Time domain methods focus on variations in the length of
the interbeat interval. Although spectral domain methods
also take this into account by breaking it down into spe-
cific components at each frequency, the focus is on fre-
quency variations. Frequency domain HRV measures the
underlying variance (power) in the heart rate pattern at
different frequencies. Short-term (two to five minute)
electrocardiogram (ECG) recordings for spectral analysis
tend to produce three peaks, a high frequency (HF) peak
between 0.15 and 0.40 Hz, a low frequency (LF) peak
between 0.04 and 0.15 Hz, and a very low frequency
(VLF) peak below 0.04 Hz [20]. Twenty-four hour ECG
recordings also provide an ultra-low frequency (ULF)
peak below 0.003 Hz [11,21]. Total power represents the
total variability in the record.
HF power reflects HRV attributable to respiratory sinus
arrhythmia, and is regarded as a marker of vagal modula-
tion of R-R intervals and a cardiac parasympathetic effect
[22]. In twenty-four hour recordings, HF power correlates
most highly with RMSSD and pNN50. LF power may be
modulated by baroreflex activity, and appears to reflect
sympathetic and parasympathetic influence on the RR
intervals [23,24]. In twenty-four hour recordings, LFBioPsychoSocial Medicine 2008, 2:12 http://www.bpsmedicine.com/content/2/1/12
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power correlates most highly with SDNN averaged over
five minute intervals. It is argued that the LF/HF ratio esti-
mates sympathovagal balance However, the measurement
of sympathovagal balance has been the subject of contro-
versy [25,26].
VLF power represents a measure of uncertain value. VLF
power may indicate thermoregulation or vasomotor activ-
ity, although this has been disputed [27,28]. It may
involve a parasympathetic component [28,29] and possi-
bly engage the rennin-aldosterone system [28,30,31]. ULF
power is far less clear, but has a strong relationship with
SDANN [11].
HRV Measures – Spectral Methods
Non-linear measures of HRV have been demonstrated to
be potentially superior in predicting sudden death in
post-infarction patient populations [32,33]. Yeragani et al
studied the effects of paroxetine and nortriptyline on HRV
in patients with ischemic heart disease and major depres-
sion employing various methods of HRV measuring,
including non-linear components of HRV. Evidence sug-
gests that non-linear assessments may provide additional
information about cardiac autonomic modulation, and
more particularly about vagal modulation [34,35]. How-
ever, these measures have not been reported in studies of
the effects of antidepressants on healthy volunteers.
Factors Affecting HRV
Various factors influence the accuracy and usefulness of
the HRV components being measured. These include the
duration of the recording and the effect of the various
physical and physiological changes that occur during the
recording period [15,36].
Spectral analysis of short-term, two to forty minute ECG
recordings provides information about the autonomic
status of the heart, reflecting mainly vagal activity [15].
Short recording times hold the advantage over long
recording times only in as far as the shorter duration
makes it possible to create physiologically fixed or station-
ary states, without too much difficulty; whereas with long-
term recordings, it is harder to create and maintain strict
standardized conditions. Longer recording times are
needed for measurement of low frequency (VLF and ULF)
components of the recoding and LF and HF components
are best suited to short-term recording times [15,37].
In addition to difficulties with maintaining a steady state,
long-term recording times also pose difficulties with anti-
depressant studies in particular. The overall effect of the
natural environment on the autonomic nervous system
and its influence on the heart is best assessed over a longer
24-hour recording period. However, they are problematic
for drug studies because the antidepressants themselves
can cause both physiological changes and behavioural
changes (e.g. increased activity) both of which may influ-
ence a twenty-four hour recording. For this reason it
seems that with drug studies, short recordings under
standardized conditions (e.g. supine) may give a purer
view of physiological changes.
Both short and long recordings have shown a relationship
between decreased HRV and mortality. Almost all of the
early predictive studies of mortality used twenty-four hour
recordings but recent studies have shown a similar rela-
tionship using shorter recordings [18].
Long-term and short-term recordings each have their
advantages and their disadvantages [36]. It is likely that
this fact that has led to the variation in approaches to the
assessment of HRV changes associated with antidepres-
sants. In addition, in research examining the effects of
antidepressants on cardiac autonomic function there is no
clear consensus as to which HRV measures are most valu-
able to assess, nor which would be the preferred record-
ing-time duration (i.e., short or long), and there is rarely
a justification given for the choice of measures in these
investigations.
The present study reviews the evidence describing changes
in HRV associated with pharmacological and physical
treatments for depression. Different measures of HRV are
examined separately as are measures from short and long
recordings. Classes of drugs (TCAs and SSRIs) are also
examined separately.
Methods
Searches were made in Medline and PsycInfo for studies
including the terms "antidepressant" (and specific antide-
pressant drugs) combined with "heart rate variability" or
"heart period variability", or "RR variability". A total of 65
potential papers resulted from these searches, in addition
to potential papers referenced in these papers. Studies
were selected for the present study based on the following
criteria. First, patients were adults (aged 18 or more) with
major depression as assessed by the Diagnostic and Statis-
tical Manual of Mental Disorders (DSM) criteria appropri-
ate for the year of the study. Second, patients were
administered an antidepressant, or ECT. Third, HRV was
assessed and could be compared either pre- or post-drug
initiation, or between a treated group and an untreated or
placebo contrast group. Fourth, if a study included two
treatment conditions it was only included if the partici-
pants were randomly assigned to treatments. Fifth, studies
using a variety of drugs were only included if the data were
broken down by each specific drug. In cases where com-
parisons between a treatment group and a control group
within the treatment group (pre-post) were possible, only
the pre-post data were included since this was the onlyBioPsychoSocial Medicine 2008, 2:12 http://www.bpsmedicine.com/content/2/1/12
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comparison in the majority of the studies. Fourteen
papers met these criteria, and since some of these exam-
ined more than one treatment a total of 23 comparisons
were possible.
Effect sizes (Cohen's d) were computed for each compari-
son. In instances where standard deviations for a particu-
lar study were not reported they were estimated as the
mean of the standard deviations reported in the other
studies in the group. Calculation of d in repeated meas-
ures requires an estimate of the correlation between the
measures at the two observations. In cases where this
could not be estimated from the data reported, the
median of test-re-test correlations for the particular HRV
measure found in the literature [19,38-48] was employed.
The variables summarized were heart rate, and time
domain measures (RMSSD, SDNN, SDANN, pNN50, and
CV), as well as frequency domain measures of HRV (HF,
LF, lnHF, and LF/HF). These values were included because
they were the measures most often reported in the studies
examined. (The log transformation of HF, lnHF, was
examined separately from HF). Studies reported one or
several measures of HRV and there was considerable
diversity in the measures reported and the length of the
recording time. In some instances missing values were cal-
culated from the available data if they were not specifi-
cally reported in the paper (e.g. CV from SDNN and HR in
five minute recordings). Data for frequency domain vari-
ables were included only if the frequency ranges reported
corresponded closely to the ranges set out by the Task
Force as some early studies used different ranges [49].
Values were grouped by length of ECG recording (short
versus 24 hour). In short recording studies, only data from
the supine condition were included, as this was the condi-
tion common to most studies. Almost all short recording
time studies used five-minute recordings. (range = 2 to 8
minutes). The statistical significance of the difference of
mean values of d from zero was calculated using one sam-
ple t tests or between group t tests as appropriate.
This paper is a review of the literature that did not require
research ethics board approval.
Results
1. HRV Response in Patients with MDD treated with TCAs
The only TCAs studied were amitriptyline, imipramine
and doxepin. Data from the studies yielded 10 compari-
sons for the effects of specific TCAs on HRV. All but two of
these comparisons used short recording times. The sum-
mary results are shown in Table 1, and the data for each
study is presented in Table 3.
In the short recording studies (where patients were
supine), treatment with the TCAs led to a sharp decrease
in all measures of HRV reported, and to an increase in
heart rate. The mean effect sizes for all measures were very
large ranging from 2.40 to 9.32 indicating a powerful
effect. However, in the two long recording studies (where
patients were ambulatory), the changes were smaller and
inconsistent. Lederbogen's [50] results showed decreases
in SDNN and SDANN, whereas Khaykin [51] found
opposite results, with significant increases in SDNN and
SDANN, as well as a decrease in RMSSD. Generally, the
findings in the short recording studies were strong and
robust, demonstrating greatly decreased HRV on a
number of measures, while the findings in the longer
recording studies were weaker and markedly inconsistent.
2. HRV Response in Patients with MDD Treated with SSRIs
Papers investigating HRV response to SSRI treatment
yielded a total of seven comparisons. The medications
investigated in these studies were fluvoxamine, paroxet-
ine, and fluoxetine. In five of the comparisons, HRV
parameters were obtained from short recordings and in
two studies 24-hour recording methods were employed
(See Table 1).
With respect to the short-term recording studies there was
a significant decrease in HR associated with the drug treat-
ment in all five studies. The change in HR was much
smaller and in a different direction than that in the TCA
studies. The only reliable change in HRV was a marginally
significant increase in SDNN. The very wide range of val-
ues for the different parameters (see Table 3) and the
small number of studies limits the power of this analysis.
As in the TCA comparisons, the results of the two long-
term (24-hour) recording studies were markedly contra-
dictory. Lederbogen [50] found little change in HR, but
again found moderate and significant decreases in SDNN
and SDANN. Conversely, Khaykin [51] found moderate
increases in SDNN and SDANN, as well as an increase in
RMSSD. In summary, the short-term recordings of
patients treated with SSRIs showed a decrease in HR, and
a marginally significant increase only in SDNN. Again, the
long-term studies were markedly contradictory, and thus
it is difficult to comment on these results.
3. HRV Responses in Patients with MDD with Other 
Treatments
Table 2 sets out the results of studies examining other
pharmacological and physical treatments of depression.
The treatments are diverse and include ECT, bupropion,
mirtazapine, nefazodone and reboxetine. The significant
changes (as reported by the authors or in our re-analysis
of the data from one study [52] were confined to an
increase in HR with nefazodone and with mirtazapine,
and decreases in all reported measures of HRV withBioPsychoSocial Medicine 2008, 2:12 http://www.bpsmedicine.com/content/2/1/12
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bupropion and mirtazapine. No significant effects were
found for ECT or reboxetine. No attempt was made to
combine the effect sizes across studies because of differ-
ences in classes of specific drug or differences in recording
time.
Discussion
The literature relating HRV to pharmacologic and physical
treatments for depression is small. In the studies that do
exist, there is considerable diversity in combinations of
HRV measures used, as well as a lack of an obvious con-
sistency in the manner in which measures were selected
for a particular study. In our meta-analysis of the available
literature, the short-term studies generated the most con-
sistent results. With the short-term recording studies,
TCAs (imipramine, doxepin, and amitriptyline) given to
patients suffering from MDD were associated with a very
large decrease in most measures of HRV and a large
increase in HR, whereas the effect of SSRIs (fluvoxamine,
fluoxetine and paroxetine) was much less clear. With
SSRIs, we did find a significant decrease in heart rate and
a marginally significant increase in only one measure of
HRV, SDNN. These changes were of a much smaller mag-
nitude compared to those associated with TCAs. Bupro-
pion and mirtazapine also were associated with decreases
in HRV. Clinically this indicates that SSRIs have less
impact on heart rate and its variability than do TCAs and
other drugs with anticholinergic effects, but that they do
still reduce HR and increase SDNN.
There were only two studies using long-term recording of
HRV, and these studies (which both looked at TCAs and
SSRIs separately) generated inconsistent results. No sys-
tematic effect was observed for either class of drug in these
two studies, and it is not possible to reconcile the differ-
ences between them as they examined different drugs in
different populations (inpatients and outpatients).
There may be an explanation for our findings of less reli-
able effects with increased recording time. In recordings
under controlled conditions (the short recordings), HRV
is primarily vagally modulated, as well as being influ-
enced by humoral factors, rhythmicity of the intrinsic car-
diac pacemaker, and the effects of respiration. In 24 hour
recordings the HRV is also influenced by activity and envi-
ronmental factors. The inconsistent findings of the long
recording studies may be due in part to the effects of the
drugs on physical activity. Because patients do not remain
supine during the recording period, changes in physical
activity over 24 hours would lead to changes in HRV not
Table 1: Patients with MDD using TCA and SSRI medication where Cohen's d reflects the difference between treatment and contrast 
condition.
Measure Heart Rate SDNN SDANN RMSSD LF LnHF HF LF/HF CV pNN50
Units bpm ms ms ms2 ms2 ms2 ms2 ratio ratio percent
TCAs – short (2–10 minute) supine
Mean Baseline Value 75.91 32.28 21.60 5.80 0.51 4.07
Mean Percent Change 20.8% -62.9% -67.3% -35.5% -79.4% -55.2%
Number of Comparisons 8 8 6 2 4 8
Mean Effect Size 4.83 -2.43 -3.34 -4.54 -0.96 -5.52
t 7.53* 9.32* 7.79* 2.40 5.85* 4.17*
p 0.00 0.00 0.00 0.25 0.01 0.00
TCAs 24 hour ambulatory
Mean Baseline Value 82.60 115.85 106.7 31.00 10.00
Mean Percent Change 7.5% -16.1% -3.7% -12.9% -30.0%
Number of Comparisons 1 2 2 1 1
Mean Effect Size 1.98 -0.20 0.31 -2.71 -3.34
t 0.10 0.10
p 0.94 0.94
SSRIs – short (2–10 minute) supine
Mean Baseline Value 76.00 28.67 26.375 26.38 5.60 0.507 3.60
Mean Percent Change -2.0% 1.0% -2.4% -1.4% -14.8% -1.9%
Number of Comparisons 4 3 4 1 1 3
Mean Effect Size -0.63 0.06 1.42 -0.15 -0.26 -0.26
t 6.33* 3.46** 0.54 2.71
p 0.01 0.07 0.63 0.11
SSRIs 24 hour ambulatory
Mean Baseline Value 81.30 30.08 118.1 30.00 9.00
Mean Percent Change -0.5% 1.7% 0.0% 16.7% 33.3%
Number of Comparisons 1 2 2 1 1
Mean Effect Size -0.10 0.51 0.43 1.76 1.76
t 0.30 0.41
p 0.82 0.75
Two studies used 24 hour monitoring. Only studies have been included where effects of specific drugs could be evaluated. Negative values indicate 
decreases in the parameter with treatment, positive values indicate increases. (* indicates p < .05, ** indicates p < .10)BioPsychoSocial Medicine 2008, 2:12 http://www.bpsmedicine.com/content/2/1/12
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directly related to the physiological effects of the drug
(and in the case of TCAs in the opposite direction to those
of the drug), and these changes would tend to obscure the
physiological effects of the drug. This idea is supported by
the fact that Khaykin [51] and Karpyak [52], both reported
increases in some measures of HRV in individuals who
responded to treatment compared to those who did not
respond. Perhaps the changes in physical activity in those
who responded to treatment that led to the increased HRV
observed in these 24 hour studies for responders relative
to non-responders decreased the reliability of the meas-
ures.
The consensus among the authors of the various studies is
that increases in HR and decreases in HRV are due, at least
in part, to the anticholinergic (i.e., antimuscarinic) prop-
erties of TCAs and of bupropion and mirtazapine, leading
to diminished cardiac vagal tone.
Nahshoni and colleagues [53] conclude that the literature
has not shown a reduction in HRV associated with SSRIs,
and they suggest that SSRIs may in fact increase vagal mod-
ulation. The present data partially support this conclu-
sion. We found a small increase in SDNN with SSRIs but
not on other measures of HRV. The studies that we
reviewed examining HRV and the treatment of depression
have generally employed small samples of depressed, but
otherwise medically well individuals, and the only relia-
ble result in our review is that there is a possibly an
increase in SDNN recorded while the participant was
supine, with drugs in this class. The fact that the other
measures do not show such a change is not in any way
conclusive, as the individual studies report a wide range of
changes in measures of HRV ranging from a reduction of
27% to an increase of 20%. This finding suggests that
methodological factors may be influencing the results.
However, our failure to find reliable changes in HRV with
SSRIs is consistent with data from a large sample of car-
diac patients as reported in the SADHART study [54]. That
study failed to show significant changes in several meas-
ures of HRV with sertraline in depressed individuals who
were not medically well. Further research is required to
clarify whether the causes of variability between studies of
SSRIs is due to differences in measurement or difference
in medications.
Table 2: Changes in HRV related to physical treatments for depression other than SSRIs or TCAs.
Measure Heart Rate SDNN SDANN RMSSD LF lnHF HF LF/HF CV pNN50
Units bpm ms ms ms ms2 ms2 ms2 ratio ratio percent
Reboxetine short supine
Mean Baseline Value 82.60 18.50 946.00 354
Mean Percent Change 5.6% -1.6% -18.9% 21.8%
Number of Comparisons 1 1 1 1
Mean Effect Size 1.32 ns -0.04 ns -0.38 ns 0.79 ns
Nefazodone short supine
Mean Baseline Value 75.80 30.08 24.50 864.00 480 2.97 3.80
Mean Percent Change -5.9% 14.3% 4.1% -5.7% -10.4% -5.7% -2.6%
Number of Comparisons 1 1 1 1 1 1 1
Mean Effect Size -1.60 * 0.08 ns 0.11 ns -0.08 ns -0.20 ns -0.16 ns -0.21 ns
Bupropion short supine
Mean Baseline Value 28.10
Mean Percent Change -42.7%
Number of Comparisons 1
Mean Effect Size -1.99 *
Mirtazapine short supine
Mean Baseline Value 66.00 49.60 6.50 5.40
Mean Percent Change 15.29% -35.7% -21.5% -25.9%
Number of Comparisons 1 1 1 1
Mean Effect Size 3.10 * -2.47 * -1.81 * -3.97 *
ECT short supine
Mean Baseline Value 548.00 264.00
Mean Percent Change -42.9% 50.4%
Number of Comparisons 11
Mean Effect Size -0.88 ns 0.84 ns
ECT 24 h
Mean Baseline Value 69.65 8.64
Mean Percent Change 6.2% 34.3%
Number of Comparisons 1 1
Mean Effect Size 0.51 ns 0.90 ns
All treatments on this table are represented by only one study except ECT where the two studies employed different recording times.
ns indicates that original study or our reanalysis showed the change as non-significant, * indicates that the original study reported that the change 
was significant (p < .05).B
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Table 3: Effect Sizes for all measures in all studies examined.
First Author 
(reference)
N Design Recording Time Drug Treatmen
t Period 
(Weeks)
*CB Effect Size (Cohen's d)
HR SDNN SDANN RMSSD LF ln HF HF LF/HF CV pNN50
TCAs Short time recording
Rechlin[55] 24 pre post 5 min amitriptyline 2 Y 4.43 -1.61 -2.97 -0.87 -9.44
Rechlin [56] 24 pre post 5 min amitriptyline 2 Y 5.52 -2.59 -2.93 -1.19 -8.85
Rechlin [57] 104 drug vs control 5 min amitriptyline 1 Y 1.60 -1.53 -1.87 -0.54 -4.76
Rechlin [58] 26 drug vs control 5 min amitriptyline 2 Y 3.81 -2.55 -3.58 -1.25 -3.97
Rechlin [59] 8 pre post 5 min amitriptyline 2 Y 6.11 -1.88 -3.66 -10.86
Rechlin [59] 8 pre post 5 min doxepin 2 Y 7.87 -3.51 -5.04 -21.44
Tulen[9] 9 pre post 8 min imipramine 4 Y 4.81 -2.44 -6.43 -3.97
Volkers[60] 24 pre post 5 min imipramine 4 Y 4.52 -3.32 -2.64 -5.52
TCAs Long time recording
Khaykin[51] 9 pre post 24 h doxepin 6 N 1.80 3.64 -2.71 -3.34
Lederbogen[50] 14 pre post 24 h amitriptyline 5 N 1.98 -2.20 -3.01
SSRIs Short time recording
Rechlin [56] 24 pre post 5 min paroxetine 2 Y -0.45 0.05 -0.61 -0.30 -0.09
Rechlin [59] 8 pre post 5 min fluvoxamine 2 Y -0.83 0.03 1.47 -0.42
Rechlin [59] 8 pre post 5 min paroxetine 2 Y -0.77 0.09 -0.39 -0.27
Straneva-Meuse[61] 17 vs control 2 min paroxetine 8 N -1.99
Volkers[60] 17 pre post 5 min fluvoxamine 4 Y -0.47 -0.15
SSRIs Long time recording
Khaykin[51] 5 pre post 24 h fluoxetine 6 N 2.24 2.81 1.76 1.76
Lederbogen[50] 14 pre post 24 h paroxetine 5 N -0.10 -1.21 -1.95
Other Treatments
Agelink[62] 25 pre-post 5 min reboxetine 3 Y 1.32 -0.04 -0.38 0.79
Agelink[63] 25 pre-post 5 min nefazodone 3 Y -1.60 0.08 0.11 -0.08 -0.20 -0.16 -0.21
Straneva-Meuse[61] 17 vs control 2 min bupropion 8 N -1.99
Tulen[9] 8 pre post 8 min mirtazapine 4 Y 4.81 -2.44 -1.81 -3.97
Karpyak[52] 11 pre post 24 h ECT ** NS 0.51 0.90
Nahshoni[53] 10 pre-post NS ECT *** NS -0.88 0.84
HR = heart rate.
CV = coefficient of variability.
NS = Not Stated.
*CB = Controlled Breathing;.
**ECT performed 3 times per week to a maximum of 10 treatments.
***ECT performed 2 times per week to a maximum of 12 treatments.BioPsychoSocial Medicine 2008, 2:12 http://www.bpsmedicine.com/content/2/1/12
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Conclusion
This review highlighted several important difficulties
associated with research in the area of HRV. First, there
exists a paucity of studies examining the effects of antide-
pressants on HRV; second, with one exception, published
studies have used very small sample sizes, ranging from n
= 6 to 24 (SSRIs), and n = 8 to 104 (TCAs); third, a variety
of methodologies were used in assessing and measuring
HRV; fourth, recording times vary between studies; and
fifth, not all studies use the same medication within med-
ication groups. The present study confirms that three
TCAs decrease HRV and increase HR. The findings for the
three SSRIs are less clear; however they do indicate a
decrease in HR and a possible increase in SDNN with SSRI
treatment. Increased HRV with SSRIs may have, theoreti-
cally at least, positive outcome implications with regard to
morbidity and mortality. The less than robust effect that
has been demonstrated may to some extent explain why
only a statistical trend to better outcomes in depressed,
recent post-MI patients receiving a SSRI was observed in
the SADHART study. Further studies of the effect of spe-
cific SSRIs on HRV using consistent methodology are
required.
List of Abbreviations
HRV: heart rate variability; HR: Heart rate; NN: Normal to
normal; SDNN: Standard deviation of all NN intervals;
SDANN: Standard deviation of the 5-minute average NN
intervals; RMSSD: Square root of the mean of the squared
differences between adjacent NN intervals; CV: Coeffi-
cient of variation; HF: High frequency; LnHF: og transfor-
mation of HF. LF: Low frequency; VLF: Very low
frequency; PNN50: the percentage of NN interval differ-
ences >50 ms from the preceding interval.
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